This statistic shows the value of the prescribed dermatology drugs market in the United States from 2016 to 2024. For 2024, it was projected that some 11.7 billion U.S. dollars will be spent on dermatologics.

This statistic shows the market value of dermatology products in Italy between ********** and **********, by category. According to data, the market value of products for atopic dermatitis amounted to **** million euros, during the year considered. Second in the ranking was the sub-segment of products for acne vulgaris, with a market value of **** million euros.

Among the top ten pharmaceutical companies, Johnson & Johnson Shanghai remained in a leading position with a *** percent share in the topical dermatological medicine market in China in 2016. China Resources Pharmaceutical Group and Bayer Healthcare followed with *** percent market share each. That year, the ten key players accounted for approximately ** percent of the topical skin medication market in China.

In fiscal year 2024, GlaxoSmithKline had an ** percent share of revenue from operations. This was an increase from the previous financial year. In financial year 2024, GSK ranked as the leading brand in the private vaccine market and dermatology segment.

In financial year 2025, in India, GSK Pharmaceuticals Limited spent approximately *** million Indian rupees on the non-ongoing project related to the corporate social responsibility (CSR). Nearly ** million Indian rupees was spent on donations of Albendazole, a medication used in the effort to eradicate Lymphatic Filariasis. In financial year 2023, GSK ranked as the leading brand in the private vaccine market and dermatology segment.

GlaxoSmithKline Pharmaceuticals Limited in India spent about ** percent of its income in material costs in fiscal year 2024. Further, ** percent of its income was spent on operating expenses, while about *** percent was spent on exchequer contributions. In financial year 2024, GSK ranked as the leading brand in the private vaccine market and dermatology segment.

In fiscal year 2024, GlaxoSmithKline Pharmaceuticals Limited earned about ** billion Indian rupees in profits before taxation. This was a significant increase compared to over ***** billion rupees as profits before tax in the previous fiscal year. In financial year 2024, GSK ranked as the leading brand in the private vaccine market and dermatology segment.

In fiscal year 2024, GlaxoSmithKline Pharmaceuticals Limited in India reported around ************ Indian rupees as earnings before interest, tax, depreciation and amortization. This was an increase compared to the previous fiscal year's ************* rupees worth EBITDA. In financial year 2024, GSK ranked as the leading brand in the private vaccine market and dermatology segment.

The equity share capital of GSK Pharmaceuticals Limited in fiscal year 2025 was valued at ***** Indian rupees. The value remained the same since financial year 2019. In financial year 2025, GSK ranked as the leading brand in the private vaccine market and dermatology segment.

The Earnings Per Share for GSK Pharmaceuticals in India during fiscal year 2024 was valued at around ** Indian rupees. This was a sharp increase from the previous year. In financial year 2024, GSK ranked as the leading brand in the private vaccine market and dermatology segment.

In financial year 2024, the book value per share for GSK Pharmaceuticals Limited stood at *** Indian rupees. This marked a slight increase in the book value for GSK shares compared to the previous year. In financial year 2024, GSK ranked as the leading brand in the private vaccine market and dermatology segment.

B. Akshikar, one of the executive directors of GlaxoSmithKline Pharmaceuticals in India, earned a remuneration of approximately ** million rupees in fiscal year 2024. This figure includes salary, performance bonuses, and other employee benefits. In financial year 2024, GSK ranked as the leading brand in the private vaccine market and dermatology segment.

GlaxoSmithKline Pharmaceuticals Limited had around ***** employees working full-time across their operations in India during financial year 2024. This figure represents a decrease from the previous year. In financial year 2024, GSK ranked as the leading brand in the private vaccine market and dermatology segment.